Eli Lilly & Co. (LLY) Misses Q1 EPS by 27c, Lowers FY EPS Guidance
Eli Lilly & Co. (NYSE: LLY) reported Q1 EPS of $1.87, $0.27 worse than the analyst estimate of $2.14. Revenue for the quarter came in at $6.81 billion versus the consensus estimate of $7.02 billion.
GUIDANCE:
Eli Lilly & Co. sees FY2021 EPS of $7.80-$8.00, versus the consensus of $8.32.
2021 Guidance | |||
Prior | Updated | ||
Revenue | $26.5 to $28.0 billion | $26.6 to $27.6 billion | |
Gross Margin % of Revenue (reported) | Approx. 77% | Unchanged | |
Gross Margin % of Revenue (non-GAAP) | Approx. 79% | Unchanged | |
Marketing, Selling & Administrative | $6.2 to $6.4 billion | Unchanged | |
Research & Development | $6.5 to $6.7 billion | $6.9 to $7.1 billion | |
Other Income/(Expense) (reported) | $(300) to $(200) million | $150 to $250 million | |
Other Income/(Expense) (non-GAAP) | $(300) to $(200) million | $(200) to $(100) million | |
Tax Rate | Approx. 15% | Approx. 13% | |
Earnings per Share (reported) | $7.10 to $7.75 | $7.03 to $7.23 | |
Earnings per Share (non-GAAP) | $7.75 to $8.40 | $7.80 to $8.00 | |
Operating Margin (reported) | Approx. 30% | Approx. 26% | |
Operating Margin (non-GAAP) | Approx. 32% | Approx. 31% | |
Non-GAAP guidance reflects adjustments presented in the earnings per share table above. | |||
For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.